Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
LNTH Stock Chart & Stats
$66.68
-$2.32(-2.39%)
At close: 4:00 PM EST
$66.68
-$2.32(-2.39%)
Day’s Range― - ―
52-Week Range$47.25 - $111.29
Previous CloseN/A
Volume177.90K
Average Volume (3M)815.98K
Market Cap
$4.40B
Enterprise Value$4.79B
Total Cash (Recent Filing)$382.01M
Total Debt (Recent Filing)$619.44M
Price to Earnings (P/E)28.0
Beta0.61
Next Earnings
Feb 19, 2026EPS Estimate
1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.27
Shares Outstanding66,311,775
10 Day Avg. Volume683,794
30 Day Avg. Volume815,977
Financial Highlights & Ratios
PEG Ratio-3.52
Price to Book (P/B)5.69
Price to Sales (P/S)4.04
P/FCF Ratio12.55
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda14.65
Forecast
1Y Price Target
$80.80Price Target Upside21.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And LiquidityA strong cash position and access to a substantial revolving credit facility provide the company with financial flexibility to fund commercialization initiatives, acquisitions, or pipeline development during a recovery phase.
Commercial ExecutionReported account stabilization and customer returns from lower-cost competitors point to improving market share and stronger demand for Pylarify's clinically differentiated offering.
Regulatory ApprovalApproval of an updated Pylarify formulation coupled with a priority regulatory designation would restore pricing flexibility and meaningfully support volume and revenue recovery.
Bears Say
Analyst Outlook And ValuationAnalyst cuts to revenue expectations and downward price-target revisions reflect a weaker outlook that may damp investor confidence until clearer evidence of durable growth appears.
Leadership TurnoverMultiple senior leadership departures, including the CEO transition and exits at the president and COO levels, introduce strategic uncertainty that could disrupt execution during a critical turnaround period.
Reimbursement And Pricing PressurePersistent 340B pricing dynamics and expected price resets create sustained net pricing pressure that could compress margins and limit revenue upside.
Lantheus News
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $47.25 and its highest was $111.29 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $4.40B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Feb 19, 2026 which is in 19 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Nov 06, 2025. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.01.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.19.
How many shares outstanding does Lantheus have?
Lantheus has 66,311,775 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.27 in its last earnings report, beating expectations of $1.26. Following the earnings report the stock price went down -6.186%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.80 (21.18% Upside)
$80.80 (21.18% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.93%
12-Months-Change
Fundamentals
Return on Equity
14.59%
Trailing 12-Months
Asset Growth
11.06%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in leadership transition, strategic acquisitions, and product expansion, particularly in the Alzheimer's imaging market. However, these positives were counterbalanced by challenges in PYLARIFY sales, gross margins, and operating income declines. Despite the lowlights, the company's strategic positioning and future growth prospects in new areas like Alzheimer's imaging suggest a cautiously optimistic outlook.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$80.80
▲(21.18% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
Currently, No data available
---